Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Loes M. Pronk"'
Autor:
Joost H van den Berg, Raquel Gomez-Eerland, Samira Michels, Maaike van Zon, Renate de Boer, Noor A M Bakker, Marit M van Buuren, Henk Mallo, Matthias Karger, Joris A van der Hage, Loes M Pronk, Marnix H Geukes Foppen, Bastiaan Nuijen, Ton N Schumacher
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Purpose Execute a phase I/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized phase III trial.Experimental Ten patients were treated
Externí odkaz:
https://doaj.org/article/dcfa2791fafa4572a3dce6276ee8be68
Autor:
Sasja F. Mulder, Marco B. Polee, Astrid A M van der Veldt, Sjoukje F. Oosting, Gerard Vreugdenhil, Loes M. Pronk, Axel Bex, Saskia Lisa Verhaart, Alfonsus J. van den Eertwegh, Albert J. ten Tije, Susanne Osanto, Danny Houtsma, Yasmin Abu-Ghanem, Maureen J.B. Aarts, Gerard Groenewegen, Frank P. J. Peters, Paul Hamberg, Maartje Los, Carla M.L. van Herpen, John B. A. G. Haanen, Metin Tascilar
Publikováno v:
Clinical Genitourinary Cancer, 19(3), 274.e1-274.e16. Elsevier
Clinical Genitourinary Cancer, 19, 274.e1-274.e16
Clinical Genitourinary Cancer, 19(3). Elsevier
Clinical genitourinary cancer, 19(3), 274.e1-274.e16. CIG MEDIA GROUP, LP
Clinical Genitourinary Cancer, 19, 3, pp. 274.e1-274.e16
Verhaart, S L, Abu-Ghanem, Y, Mulder, S F, Oosting, S, Van Der Veldt, A, Osanto, S, Aarts, M J B, Houtsma, D, Peters, F P J, Groenewegen, G, Van Herpen, C M L, Pronk, L M, Tascilar, M, Hamberg, P, Los, M, Vreugdenhil, G, Polee, M, Ten Tije, A J, Haanen, J B A G, Bex, A & van den Eertwegh, A J 2021, ' Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands : An Analysis of Toxicity, Efficacy, and Predictive Markers ', Clinical Genitourinary Cancer, vol. 19, no. 3, pp. 274.e1-274.e16 . https://doi.org/10.1016/j.clgc.2020.10.003
Clinical Genitourinary Cancer, 19, 274.e1-274.e16
Clinical Genitourinary Cancer, 19(3). Elsevier
Clinical genitourinary cancer, 19(3), 274.e1-274.e16. CIG MEDIA GROUP, LP
Clinical Genitourinary Cancer, 19, 3, pp. 274.e1-274.e16
Verhaart, S L, Abu-Ghanem, Y, Mulder, S F, Oosting, S, Van Der Veldt, A, Osanto, S, Aarts, M J B, Houtsma, D, Peters, F P J, Groenewegen, G, Van Herpen, C M L, Pronk, L M, Tascilar, M, Hamberg, P, Los, M, Vreugdenhil, G, Polee, M, Ten Tije, A J, Haanen, J B A G, Bex, A & van den Eertwegh, A J 2021, ' Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands : An Analysis of Toxicity, Efficacy, and Predictive Markers ', Clinical Genitourinary Cancer, vol. 19, no. 3, pp. 274.e1-274.e16 . https://doi.org/10.1016/j.clgc.2020.10.003
Nivolumab has been approved as second-line treatment for advanced renal cell carcinoma in Europe. We performed a real-world analysis to validate this practice. The study included 264 patients from 24 hospitals in the Netherlands. We found that toxici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86a6df231f2d91880aae6ffa2cce815c
https://pure.eur.nl/en/publications/4db281aa-3dad-4c8e-a105-2442dffa9661
https://pure.eur.nl/en/publications/4db281aa-3dad-4c8e-a105-2442dffa9661
Autor:
Lindsay G Grijpink-Ongering, Sandra Adriaansz, Pia Kvistborg, Christian U. Blank, John B. A. G. Haanen, Annemarie Bruining, Bart A. van de Wiel, Karolina Sikorska, Daisy Philips, Lorenzo F. Fanchi, Sarah Warren, Ton N. Schumacher, Oscar Krijgsman, Daniel S. Peeper, Annegien Broeks, Harm van Tinteren, Elisa A. Rozeman, H. Mallo, Marlous van den Braber, Loes M. Pronk, Sylvia ter Meulen, Alexander C.J. van Akkooi, Johannes V. Van Thienen, Rachel M. Gittelman
Publikováno v:
Nature Medicine. 24:1655-1661
Adjuvant ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) both improve relapse-free survival of stage III melanoma patients1,2. In stage IV disease, the combination of ipilimumab + nivolumab is superior to ipilimumab alone and also appears to be mo
Autor:
Christian U. Blank, Sofie Wilgenhof, J.B.A.G. Haanen, Loes M. Pronk, Maartje W. Rohaan, J.H. van den Berg, B.A. van de Wiel, T.N. Schumacher, A. Sari, Ferry Lalezari, H. van Tinteren, Raquel Gomez-Eerland, H. Mallo, M. van Zon, Bastiaan Nuijen, J.V. van Thienen, M.H. Geukes Foppen, J. H. Beijnen, R. De Boer, Noor A. M. Bakker
Publikováno v:
Annals of Oncology. 30:v481-v482
Background Adoptive cell therapy (ACT) with T cell receptor (TCR) gene modified peripheral blood T cells creates large pools of tumor reactive T cells. Based on preclinical validation we have selected a high affinity MART-1-specific TCR for TCR gene
Autor:
J.B.A.G. Haanen, S. Ter Meulen, Christian U. Blank, Willem M.C. Klop, H. Van Thienen, A.C.J. van Akkooi, B.A. van de Wiel, Loes M. Pronk, H. van Tinteren, Annegien Broeks, Lindsay G Grijpink-Ongering, Lorenzo F. Fanchi, Oscar Krijgsman, Daniel S. Peeper, Elisa A. Rozeman, Karolina Sikorska, Annemarie Bruining, T.N. Schumacher
Publikováno v:
Annals of Oncology. 29:x42
Autor:
Loes M. Pronk, B.A. van de Wiel, Sofie Wilgenhof, J.V. van Thienen, J. Lijnsvelt, Karolina Sikorska, A. Sari, W. Uyterlinde, J.B.A.G. Haanen, C. Blank, H. Mallo, M.A. Vollenbergh, Lindsay G Grijpink-Ongering, Elisa A. Rozeman, Sandra Adriaansz, J.W.B. de Groot, Birthe Heeres
Publikováno v:
Annals of Oncology. 29:viii736
Autor:
Christian U. Blank, Marco Donia, Bastiaan Nuijen, J.H. van den Berg, J.V. van Thienen, R. De Boer, A.C.J. van Akkooi, Maartje W. Rohaan, M.H. Geukes Foppen, T.H. Borch, Loes M. Pronk, Sofie Wilgenhof, J.B.A.G. Haanen, Özcan Met, M. van Zon, E.A.M. Bakker, Inge Marie Svane
Publikováno v:
Annals of oncology, 29. Oxford University Press
Autor:
Loes M. Pronk, Georgina V. Long, Alexander M. Menzies, Maria Gonzales, Alexander C.J. van Akkooi, Christian U. Blank, Johan Hansson, James Larkin, Elisa A. Rozeman, Christoph Hoeller, Myles Smith, Richard A. Scolyer
Publikováno v:
Journal of Clinical Oncology. 36:TPS9606-TPS9606
TPS9606Background: The outcome of high risk stage III melanoma patients (pts) is poor, with a 5 year overall survival (OS) rate of < 50%. Adjuvant (adj) high dose IPI significantly improves 5 year progression free survival (PFS) and OS and adj NIVO i
Autor:
Christian U. Blank, Loes M. Pronk, Maartje W. Rohaan, Marnix H Geukes Foppen, Bastiaan Nuijen, John B. A. G. Haanen, Raquel Gomez-Eerland, Joost H. van den Berg, Renate de Boer, Johannes V. Van Thienen, Bart A. van de Wiel, Maaike van Zon, Eleonora A.M. Bakker
Publikováno v:
Journal of Clinical Oncology. 36:TPS9602-TPS9602
TPS9602Background: Since the introduction of targeted therapy and checkpoint inhibitors, the historically poor prognosis of patients with unresectable stage IIIc/IV melanoma has greatly improved, w...
Autor:
Christian U. Blank, J.B.A.G. Haanen, M.H. Geukes Foppen, Johannes V. Van Thienen, Jules Gadiot, Loes M. Pronk, Elisa A. Rozeman, Marcel A. Deken
Publikováno v:
Annals of Oncology. 28:v446